Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ Cardiovascular Innov...arrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
Cardiovascular Innovations and Applications
Article . 2016 . Peer-reviewed
License: CC BY NC
Data sources: Crossref
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
Cardiovascular Innovations and Applications
Article
License: CC BY NC
Data sources: UnpayWall
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
versions View all 2 versions
addClaim

This Research product is the result of merged Research products in OpenAIRE.

You have already added 0 works in your ORCID record related to the merged Research product.

Coronary Artery Chronic Total Occlusion

Authors: Calvin Choi; Ki Park; Nayan Agarwal; R. David Anderson;

Coronary Artery Chronic Total Occlusion

Abstract

Coronary artery chronic total occlusion (CTO) is defined as an occluded coronary artery segment without anterograde flow for at least three months. It can be classified as a “true” or “functional” CTO based on flow characteristics. In “true” CTO, there is no anterograde flow. In “functional” CTO, there is minimal anterograde flow through the occluded segment of the coronary artery. CTO is a common finding during coronary angiography and its prevalence may vary depending on the reported literature. Among patients without previous coronary artery bypass grafting (CABG), CTO is found in about 20–30% of the patients. CTO may develop insidiously over a period of time and involve a complex interplay between intracellular and extracellular factors, smooth muscle and foam cells, calcification, and neovascularization. There is a growing body of evidence to support that CTO revascularization may improve clinical outcome when compared to medical management. Both the European and American cardiovascular societies support CTO revascularization with a class 2a recommendation (level of evidence B). Historically, due to low procedural success rate, apparent inefficient resource utilization, potential increase in complication rates and uncertain clinical benefits, only about 10–20% of patients with CTO are treated with percutaneous coronary intervention (PCI). Recent advances using novel and innovative techniques with dedicated equipment have significantly improved the procedural success rate for CTO PCI to about 90% in the hands of experienced operators. With increasing interest in CTO PCI coupled with increased educational effort, CTO PCI likely will become more accessible to patients in need of CTO revascularization. Ongoing advancement in innovative techniques and equipment will continue to improve procedural success rates and reduce procedural complication rate for CTO PCI. Furthermore, there are a number of prospective clinical trials on the horizon which should help define the clinical benefits and limitations of CTO PCI in the near future.

Related Organizations
Keywords

RC666-701, Diseases of the circulatory (Cardiovascular) system

  • BIP!
    Impact byBIP!
    citations
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    1
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    Average
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    Average
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    Average
Powered by OpenAIRE graph
Found an issue? Give us feedback
citations
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
1
Average
Average
Average
gold